Clinical Trials Logo

Beta Thalassaemia clinical trials

View clinical trials related to Beta Thalassaemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT03275051 Active, not recruiting - Beta Thalassaemia Clinical Trials

Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL)

Start date: October 4, 2017
Phase: N/A
Study type: Interventional

OTL-300 is a gene therapy drug product consisting of autologous hematopoietic stem/progenitor cluster of differentiation (CD) 34+ cells genetically modified with a lentiviral vector (GLOBE) encoding the human beta globin gene. The TIGET-BTHAL is a phase I/II study evaluating safety and efficacy of OTL-300 in subjects with transfusion dependent beta-thalassemia for two years post gene-therapy. Subjects with rare disease who have undergone gene therapy are followed for efficacy and possible delayed adverse events. Thus, this study is designed to follow patients who have received gene therapy on TIGET-BTHAL for an additional six years (for a total of eight years).